文献速递生殖医学产科

SARS-CoV-2、生育力与辅助生殖

SARS-CoV-2, fertility and assisted reproduction.
PubMed 文献 · Hum Reprod Update · 2023-01-01

本文综述截至2022年10月5日的文献,评估SARS-CoV-2感染、COVID-19疾病及疫苗接种对人类生育力和辅助生殖的影响。共纳入148篇论文,认为COVID-19不属性传播疾病,既往无症状或轻症感染似乎不负面影响ART结局,无证据表明疫苗对精液参数、卵巢功能或ART结局有负面影响。

要点

  • COVID-19不能被视为性传播疾病,重症患者精液中可检出SARS-CoV-2 RNA,轻中症未检出。
  • 既往无症状或轻症SARS-CoV-2感染似乎不负面影响ART的实验室和临床结局。
  • 无证据表明SARS-CoV-2疫苗对精液参数、卵巢功能、卵巢储备或卵泡发生有负面影响。

核心结论

  • 本综述汇总SARS-CoV-2感染或COVID-19对生育力和辅助生殖影响的现有知识,同时识别研究空白并提出未来研究方向。

研究设计与样本

  • 检索PUBMED/MEDLINE和WHO COVID-19数据库,从建库至2022年10月5日,聚焦SARS-CoV-2与配子、胚胎、生殖功能、生育力和ART。
  • 排除非英语研究、2020年前发表的论文、综述和非同行评议出版物,最终纳入148篇论文。

主要发现

  • 重症COVID-19患者精液中检出SARS-CoV-2 RNA,轻/中度疾病患者精液中未检出。
  • SARS-CoV-2感染可损害精子发生,但似乎在一个生精周期后恢复。
  • COVID-19期间和之后睾酮水平似乎较低,但缺乏长期数据,疾病严重程度可能与睾酮水平相关。
  • 女性既往无症状或轻症SARS-CoV-2感染似乎不负面影响ART的实验室和临床结局。
  • 无证据表明SARS-CoV-2疫苗对精液参数、精子发生、卵巢功能、卵巢储备或卵泡发生有负面影响,但已记录对月经周期的短暂影响。

关键数值与推荐

  • COVID-19不能被视为性传播疾病。
  • 子宫肌层、子宫、卵巢或输卵管中ACE2与TMPRSS2无共表达。
  • 卵母细胞似乎具有易感SARS-CoV-2感染的受体和蛋白酶机制,但迄今未检测到卵母细胞中的病毒RNA。
  • 大多数研究未报告COVID-19对卵巢储备、卵巢功能或卵泡液参数有显著影响。
  • 抗SARS-CoV-2刺突蛋白抗体与Syncytin-1之间不存在交叉反应性。

临床怎么用

  • COVID-19后考虑妊娠的女性可能受益于甲状腺功能障碍筛查。
  • 尚无关于COVID-19康复与ART之间最低所需间隔(如有)的数据。
  • mRNA SARS-CoV-2疫苗对患者紧接其后ART周期的表现无影响,接种后妊娠率与未接种患者相似。

局限性

  • 睾酮水平长期数据缺乏。
  • COVID-19康复与ART之间最低所需间隔(如有)尚无数据。
  • 本综述识别了研究空白并提出未来研究建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2020, SARS-CoV-2 and the COVID-19 pandemic had a huge impact on the access to and provision of ART treatments. Gradually, knowledge of the virus and its transmission has become available, allowing ART activities to resume. Still, questions on the impact of the virus on human gametes and fertility remain. OBJECTIVE AND RATIONALE: This article summarizes published data, aiming to clarify the impact of SARS-CoV-2 and the COVID-19 disease on human fertility and assisted reproduction, as well as the impact of vaccination, and from this, provide answers to questions that are relevant for people contemplating pregnancy and for health care professionals. SEARCH METHODS: PUBMED/MEDLINE and the WHO COVID-19 database were searched from inception to 5 October 2022 with search terms focusing on 'SARS-CoV-2' and gametes, embryos, reproductive function, fertility and ART. Non-English studies and papers published prior to 2020 were excluded, as well as reviews and non-peer reviewed publications. Full papers were assessed for relevance and quality, where feasible. OUTCOMES: From the 148 papers included, the following observations were made. The SARS-CoV-2-binding proteins, angiotensin-converting enzyme 2 (ACE2) and type II transmembrane serine protease (TMPRSS2), are expressed in the testis, but co-expression remains to be proven. There is some evidence of SARS-CoV-2 RNA in the ejaculate of COVID-19 patients with severe disease, but not in those with mild/moderate disease. SARS-CoV-2 infection can impair spermatogenesis, but this seems to resolve after one spermatogenic cycle. Testosterone levels seem to be lower during and after COVID-19, but long-term data are lacking; disease severity may be associated with testosterone levels. COVID-19 cannot be considered a sexually transmitted disease. There is no co-expression of ACE2 and TMPRSS2 in the myometrium, uterus, ovaries or fallopian tubes. Oocytes seem to have the receptors and protease machinery to be susceptible to SARS-CoV-2 infection; however, viral RNA in oocytes has not been detected so far. Women contemplating pregnancy following COVID-19 may benefit from screening for thyroid dysfunction. There is a possible (transient) impact of COVID-19 on menstrual patterns. Embryos, and particularly late blastocysts, seem to have the machinery to be susceptible to SARS-CoV-2 infection. Most studies have not reported a significant impact of COVID-19 on ovarian reserve, ovarian function or follicular fluid parameters. Previous asymptomatic or mild SARS-CoV-2 infection in females does not seem to negatively affect laboratory and clinical outcomes of ART. There are no data on the minimum required interval, if any, between COVID-19 recovery and ART. There is no evidence of a negative effect of SARS-CoV-2 vaccination on semen parameters or spermatogenesis, ovarian function, ovarian reserve or folliculogenesis. A transient effect on the menstrual cycle has been documented. Despite concerns, cross reactivity between anti-SARS-CoV-2 spike protein antibodies and Syncytin-1, an essential protein in human implantation, is absent. There is no influence of mRNA SARS-CoV-2 vaccine on patients' performance during their immediate subsequent ART cycle. Pregnancy rates post-vaccination are similar to those in unvaccinated patients. WIDER IMPLICATIONS: This review highlights existing knowledge on the impact of SARS-CoV-2 infection or COVID-19 on fertility and assisted reproduction, but also identifies gaps and offers suggestions for future research. The knowledge presented should help to provide evidence-based advice for practitioners and couples contemplating pregnancy alike, facilitating informed decision-making in an environment of significant emotional turmoil.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Ata B, Vermeulen N, Mocanu E, et al. SARS-CoV-2, fertility and assisted reproduction. Hum Reprod Update. 2023. PMID: 36374645. doi:10.1093/humupd/dmac037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。